玻璃体腔内注射康柏西普治疗湿性年龄相关性黄斑变性的真实世界结果

Real-world outcomes in patients undergoing intravitreal conbercept treating wet age-related macular degeneration

目的探讨玻璃体腔内注射康柏西普治疗湿性年龄相关性黄斑变性(AMD)的临床效果。方法选取2015年6月至2018年6月首都医科大学附属北京安贞医院眼科收治的湿性AMD患者40例,共42只患眼,所有患眼首次治疗均常规给予0.5 mg康柏西普玻璃体腔内注药,根据随访检查决定是否再次注射治疗,比较治疗前和治疗3、6、9、12个月后患眼的视力、视网膜中心厚度和光学相干断层扫描的影像改变。结果治疗12个月后42只患眼平均最佳矫正视力较治疗前显著改善[(48±12)个字母比(42±12)个字母],平均视网膜中心厚度显著降低[(279±58)μm比(359±77)μm],差异均有统计学意义(均P<0.001),患眼视网膜内液体减少10只(23.8%),视网膜下液体减少17只(40.5%),视网膜色素上皮脱离消失6只(14.3%)。12个月内平均注射康柏西普(3.5±1.7)针,未发生严重的眼部及全身不良反应。结论真实世界研究结果证实,玻璃体腔内注射康柏西普治疗湿性AMD是有效、安全的。

Objective To investigate the clinical outcomes of intravitreal conbercept treating wet age-related macular degeneration( AMD). Methods A total of 42 eyes from 40 consecutive AMD patients admitted in Beijing Anzhen Hospital,Capital Medical University were evaluated,from June 2015 to June 2018.All cases routinely received intravitreal injection of 0. 5 mg conbercept. The criteria for retreatment was based on the results of follow-up examination. Visual acuity( VA) and central retinal thickness( CRT) at baseline,3,6,9 and 12 months after treatment were collected. Results The mean best corrected VA improved significantly from( 42 ± 12) letters at baseline to( 48 ± 12) letters after 12 months of treatment( P < 0. 001). The CRT decreased from( 359 ± 77) μm to( 279 ± 58) μm after 12 months of treatment( P < 0. 001). Optical coherence tomography images revealed that intra-retinal fluid decreased in 10 eyes( 23. 8%),sub-retinal fluid decreased in 17 eyes( 40. 5%) and retinal pigment epithelium detachment disappeared in 6 eyes( 14. 3%). Patients underwent a mean of( 3. 5 ± 1. 7) injections during the follow-up of 12 months. No severe ocular or systemic adverse events were observed. Conclusion Intravitreal conbercept is an effective and safe treatment for wet AMD.